Serum protein binding of tolterodine and its major metabolites in humans and several animal species

This publication has 20 references indexed in Scilit:

• Dose-ranging study of tolterodine in patients with detrusor hyperreflexia
  Neurourology and Urodynamics, 1998
• Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine*
  Clinical Pharmacology & Therapeutics, 1998
• Efficacy and safety of tolterodine in patients with detrusor instability: a dose‐ranging study
  British Journal of Urology, 1998
• Antimuscarinic Potency and Bladder Selectivity of PNU‐200577, a Major Metabolite of Tolterodine
  Basic & Clinical Pharmacology & Toxicology, 1997
• Tolterodine – a new bladder-selective antimuscarinic agent
  European Journal of Pharmacology, 1997
• Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation
  World Journal of Urology, 1997
• Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity
  Neurourology and Urodynamics, 1995
• A Simple and Rapid Fluorometric Determination Method of α1-Acid Glycoprotein in Serum Using Quinaldine Red
  Pharmaceutical Research, 1994
• Alpha1-acid glycoprotein concentration and protein binding in trauma
  Clinical Pharmacology & Therapeutics, 1982
• Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α₁Acid Glycoprotein
  New England Journal of Medicine, 1978